Insider
AbbVie Inc.ABBV

AbbVie reports successful study data and new regulatory decisions

AbbVie announced successful completion of phase trials and new regulatory decisions between Sept. 30 and Oct. 13, 2026.

Verified against 5 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white wooden desk on hallway inside building
Photo by Brandon Holmes on Unsplash

Key points

  • Temab‑A received two FDA breakthrough therapy designations for colorectal cancer and non‑small cell lung cancer.
  • The positive data involve patients with atopic dermatitis, non‑segmental vitiligo, colorectal and non‑small cell lung cancer, and Crohn’s disease.
  • EU approval of RINVOQ and FDA breakthrough therapy designations for Temab‑A confirm regulators’ positive view of safety and efficacy potential.

What happened

Temab‑A received two FDA breakthrough therapy designations for colorectal cancer and non‑small cell lung cancer.

Who is affected

The positive data involve patients with atopic dermatitis, non‑segmental vitiligo, colorectal and non‑small cell lung cancer, and Crohn’s disease.

Evidence assessment

EU approval of RINVOQ and FDA breakthrough therapy designations for Temab‑A confirm regulators’ positive view of safety and efficacy potential.

Next steps

The announcements gave no specific dates for further steps; the company did not disclose when it will file approval applications or start additional studies.

Original sources

  1. AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026September 30, 2026SHA-256 of our archived copy 61e05b67d02c…
  2. AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental VitiligoOctober 1, 2026SHA-256 of our archived copy a1d9953a34d6…
  3. AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCOctober 7, 2026SHA-256 of our archived copy 5f5ba67ce3dc…
  4. New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseaseOctober 11, 2026SHA-256 of our archived copy cf2a68fbb8e4…
  5. AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's DiseaseOctober 13, 2026SHA-256 of our archived copy 2db255fc2b58…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards